Sustained complete remission of recurrent acute myeloid leukaemia with a single dose of gemtuzumab ozogamicin and low-dose interleukin-2 maintenance

被引：1

作者：

Radsak, MP ^{[1
]}

Salih, HR ^{[1
]}

Sökler, M ^{[1
]}

Kanz, L ^{[1
]}

Denzlinger, C ^{[1
]}

机构：

[1] Univ Tubingen, Dept Haematol Oncol, Sch Med, D-72076 Tubingen, Germany

来源：

LEUKEMIA | 2002年 / 16卷 / 09期

关键词：

D O I：

10.1038/sj.leu.2402594

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1870 / 1871

页数：2

共 7 条

[1]

ADLER A, 1988, BLOOD, V71, P709

[2]

Denzlinger C, 2000, BRIT J HAEMATOL, V108, P93

[3] A MONOCLONAL-ANTIBODY REACTIVE WITH NORMAL AND LEUKEMIC HUMAN MYELOID PROGENITOR CELLS [J].

GRIFFIN, JD ;

LINCH, D ;

SABBATH, K ;

LARCOM, P ;

SCHLOSSMAN, SF .

LEUKEMIA RESEARCH, 1984, 8 (04) :521-534

[4]

MELONI G, 1994, BLOOD, V84, P2158

[5] Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: A phase I study of an anti-CD33 calicheamicin immunoconjugate [J].

Sievers, EL ;

Appelbaum, FR ;

Spielberger, RT ;

Forman, SJ ;

Flowers, D ;

Smith, FO ;

Shannon-Dorcy, K ;

Berger, MS ;

Bernstein, ID .

BLOOD, 1999, 93 (11) :3678-3684

[6] Mylotarg: antibody-targeted chemotherapy comes of age [J].

Sievers, EL ;

Linenberger, M .

CURRENT OPINION IN ONCOLOGY, 2001, 13 (06) :522-527

[7] Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse [J].

Sievers, EL ;

Larson, RA ;

Stadtmauer, EA ;

Estey, E ;

Löwenberg, B ;

Dombret, H ;

Karanes, C ;

Theobald, M ;

Bennett, JM ;

Sherman, ML ;

Berger, MS ;

Eten, CB ;

Loken, MR ;

van Dongen, JJM ;

Bernstein, ID ;

Appelbaum, FR .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (13) :3244-3254

← 1 →